Skip to main content
. 2021 Apr 6;12(4):356. doi: 10.1038/s41419-021-03626-7

Fig. 5. Identification of miRNAs binding to hsa_circ_101555 that modulate the proliferation, cell cycle, migration, and invasion of HCC cells via miR-145-5p.

Fig. 5

A Heatmap analyses exhibit differentially expressed miRNAs in HCC with |log2fold-change | > 1.0 and P < 0.05. B Venn analysis between predicted miRNA targeted by hsa_circ_101555 and differentially expressed miRNAs implying that miR-145-5p is involved in HCC. C Kaplan–Meier curves imply that patients with low miR-145-5p levels have a poorer 10-year overall survival. D Expression of miR-145-5p in 10 HCC tumor tissues and adjacent normal tissues, measured by qRT-PCR (***P < 0.001). E Pearson correlation analyses showing a correlation between hsa_circ_101555 and miR-145-5p expression (n = 20). F, G Schematic of hsa_circ_101555 wild-type (wt) and mutant (mut) luciferase reporter vectors. Luciferase reporter assay in HEK293T cells co-transfected with miRNA mimics, hsa_circ_101555-wt and mutant (mut) luciferase reporter vectors. H Expression of miR-145-5p analyzed by qRT-PCR in HCCLM3 and HepG2 cells transfected with siRNA-hsa_circ_101555-#1, siRNA-hsa_circ_101555-#3, or siRNA-NC (**P < 0.01; ***P < 0.001; n = 5). I, J Viability of HCCLM3 and HepG2 cells after co-transfection with siRNA-hsa_circ_101555 and miR-145-5p inhibitor measured using WST-1 assays (*P < 0.05;**P < 0.01; ***P < 0.001; n = 4). K, L Cell proliferation ability of HCCLM3 and HepG2 cells co-transfected with siRNA-hsa_circ_101555 and miR-145-5p inhibitor evaluated by colony formation assay (*P < 0.05;**P < 0.01; ***P < 0.001; n = 4). M, N Cell migration or invasion assays performed in HCCLM3 and HepG2 cells co-transfected with siRNA-hsa_circ_101555 and miR-145-5p inhibitor using transwell chamber, with or without Matrigel, respectively (**P < 0.01; ***P < 0.001; n = 4).